# Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

> **NCT01822522** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- HIV Infection
- Metastatic Malignant Solid Neoplasm
- Recurrent Malignant Solid Neoplasm
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Cabozantinib S-malate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01822522
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-21
- **Primary completion:** 2019-05-22
- **Final completion:** 2021-05-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822522, "Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01822522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*